Targeting hard-to-treat cancers

Secko, David
April 2005
CMAJ: Canadian Medical Association Journal;4/12/2005, Vol. 172 Issue 8, p993
Academic Journal
Reveals that researcher Ellen Weisberg and colleagues have identified the mechanism for imatinib resistance in chemotherapy with chronic myelogenous leukemia (CML). Information on the new drug designed by the Weisberg and colleagues that may overcome the problem in treating CML; Details on the research.


Related Articles

  • Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib. Stegmeier, F.; Warmuth, M.; Sellers, W. R.; Dorsch, M. // Clinical Pharmacology & Therapeutics;May2010, Vol. 87 Issue 5, p543 

    An increased understanding of the molecular etiology of cancer has enabled the development of novel therapies that are collectively referred to as molecular targeted agents. Unlike the drugs used in conventional chemotherapy, these agents are designed to specifically interfere with key molecular...

  • Management Options for Refractory Chronic Myeloid Leukemia: Considerations for the Elderly. Breccia, Massimo; Alimena, Giuliana // Drugs & Aging;2013, Vol. 30 Issue 7, p467 

    Despite the excellent results obtained with standard-dose imatinib as first-line therapy for chronic myeloid leukemia in the chronic phase, one third of patients do not achieve an optimal response and require alternative therapies due to the emergence of drug resistance. Studies of resistance...

  • Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. Abdullah Altintas; Timucin Cil; Ilhan Kilinc; Muhammet Kaplan; Orhan Ayyildiz // Journal of Neuro-Oncology;Aug2007, Vol. 84 Issue 1, p103 

    Summary  Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22. Imatinib mesylate is a potent and selective inhibitory of the BCR/ABL tyrosine kinase. Imatinib is a first choice of treatment of...

  • Feature: Targeting leukaemia.  // Australian Life Scientist;10/15/2009, p18 

    Australian-US pharmaceutical company, ChemGenex, is close to bringing a new targeted drug to market, with implications for chronic myelogenous leukaemia and other blood-borne cancers.

  • Chronic myeloid leukemia: Standard treatment options.  // American Journal of Health-System Pharmacy;12/1/2006 Supplement, Vol. 63, pS10 

    The article examines historical treatment options for chronic myeloid leukemia as an alternative to molecular-targeted kinase inhibitors, such as imatinib. Kinase inhibitors are the first choice, but previously-used chemotherapeutic drugs are the alternative in the case of patients resistant to...

  • Clinical update 2007: Making strides in the management of chronic myeloid leukemia. Frame, David // American Journal of Health-System Pharmacy;12/15/2007 Supplement, Vol. 64 Issue 15, pS2 

    The article reports on the developments made in the management of chronic myeloid leukemia (CML). CML is a hematopoietic stem cell cancer which affects approximately 1 in 100,000 Americans. Early treatments fro CML involved standard cytoreductive chemotherapies such as busulfan or hydroxyurea....

  • Chronic myeloid leukemia in 2007. Sessions, Jolynn // American Journal of Health-System Pharmacy;12/15/2007 Supplement, Vol. 64 Issue 15, pS4 

    Purpose. Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed. Summary. CML is a myeloproliferative disorder that affects all lineages of hematopolesis. Final...

  • Targeted chronic myeloid leukemia therapy: Seeking a cure. Fausel, Christopher // American Journal of Health-System Pharmacy;12/15/2007 Supplement, Vol. 64 Issue 15, pS9 

    Purpose. This article focuses on imatinib, how it has altered CML therapy, clinical trials that are the basis for its efficacy, and adverse effects associated with its current clinical use. Summary. Maintaining patients with CML in chronic phase (CP) yields the prospect of improved long-term...

  • New strategies in controlling drug resistance in chronic myeloid leukemia. Frame, David // American Journal of Health-System Pharmacy;12/15/2007 Supplement, Vol. 64 Issue 15, pS16 

    Purpose. Imatinib has been quite effective in maintaining patients with CML in the chronic phase (CP); however, some patients develop imatinib resistance. This review addresses the mechanisms underlying imatinib resistance and the strategies currently being used to overcome that resistance....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics